Opinion

Video

ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Author(s):

Jason Porter, MD

Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.

Video content above is prompted by the following questions:

  1. How do these four trials address the unmet needs of patients with NSCLC?
  2. After the presentation of advancements in NSCLC research at ASCO, how do you envision the future of personalized medicine in this disease?
  3. Please discuss any other data in NSCLC released at ASCO 2024 that you find noteworthy to share with colleagues.
  4. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of NSCLC? What can we look forward to through the end of the year and beyond?
Related Videos
Ana Baramidze, MD, PhD
Ticiana Leal, MD, Emory Winship Cancer Institute
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Joseph Mikhael, MD, an expert on multiple myeloma
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Related Content
Martin Dietrich, MD, PhD
October 24th 2024

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

Maggie L. Shaw
Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Umit Tapan, MD, Boston Medical Center
October 18th 2024

Expanding Access to NSCLC Innovations: Challenges and Opportunities

Maggie L. Shaw
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
FDA approved | Image Credit: © wladimir1804 -stock.adobe.com
October 16th 2024

FDA Approves Optune Lua Device in NSCLC

Maggie L. Shaw
Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.
Emory Winship Cancer Institute | Image: Emory
October 14th 2024

In Cancer Care, Innovation Comes at a Cost

Rose McNulty
Ticiana Leal, MD, Emory Winship Cancer Institute
October 12th 2024

Early Biomarker Testing Key for Perioperative NSCLC Success

Rose McNulty Maggie L. Shaw
Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).
LC and breathing | Image Credit: © Cozine-stock.adobe.com
October 10th 2024

Breathomics: A Low-Cost Solution for Early Lung Cancer Diagnosis?

Kimberly Rath, PharmD
Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo